This paragraph appears to be key to understanding their experimental therapies.
AVI has the manufacturing capacity to produce clinical-grade NEUGENE antiviral therapeutics, targeting viral pathogens, for a limited number of patients within days. NEUGENES are synthetic compounds that mirror a critical portion of a disease-causing organism's genetic code and bind to specific portions of the target genetic sequence. Like a key in a lock, NEUGENE antisense compounds are designed to match up precisely with a specific gene or viral sequence, blocking its function.
To the best of my recollection, in a nutshell, DNA is composed of two strands, a sense strand which is transcribed into RNA to make protein and an antisense strand which runs in the opposite direction. For example, if a sequence of DNA for a gene from the sense strand reads...
CTGAATTTACGGAATCAG then the antisense strand would read
...since the base adenine, A, binds to the base thymine, T, and the base cytosine, C, binds to the base guanine, G. In RNA the base T is replaced by uracil, U. It's a fairly common experimental procedure to try to knock out the function of a gene by using antisense RNA. The antisense RNA will have the opposite sequence of RNA which is used to synthesize proteins at the ribosome and will bind to RNA preventing its translation into protein. By using antisense RNA my best guess is that they are trying to knock out the function of a specific gene. If this type of therapy is already in clinical trial, then it suggests that they've had success using animal models knocking out specific genes. I would be very interested in knowing which specific genes they were targetting for MS!